'MyBioPharmaSpace'

Where did these industry agreements come from, and why? In the first episode of a two-part special, we discuss the genesis of the Australian government's agreements with the industry, based on personal experience, why they emerged as a solution to a decade-old challenge, and the problem they were aiming to solve.

Opthea, once one of Australia's most important emerging biotechnology companies, has announced it will redirect the development of OPT-302 to lymphangioleiomyomatosis, or LAM, a rare pulmonary disease with significant unmet need.

Nobody suggests that the plethora of regular changes to medicine prices, both increases and decreases, including to ensure ongoing subsidised access, undermines or ‘threatens’ the PBS. Governments respond to external realities that impact the PBS almost monthly. If it has to respond to the MFN threat through pricing policies, who cares? Just do it. The more they deny this reality, the harder it will become.

Sandoz has produced a paper from a biosimilar-focused summit it hosted in Canberra in March, including proposals that aim to increase the uptake of biosimilar medicines.

Senator David Pocock asked the official for the start date of the three- to six-month timeline, noting that the PBAC recommended earlier reimbursement access for paediatric patients three months ago.

Two large statewide trials led by the University of Newcastle have shown that pharmacist-led services can safely and effectively manage uncomplicated urinary tract infections and supply oral contraceptives for women, improving timely access to care and ensuring referral to GPs when clinically required.

Health Department officials told a Senate Estimates hearing yesterday that they are monitoring the US 'Most Favored Nation' pharmaceutical pricing policy closely, developing responses as necessary, and continue to see a steady stream of submissions and reimbursement outcomes.

The Marie Krogh Young Women in Science Prize is expanding into New Zealand as it returns for a second year, bringing recognition, funding and networking to early and mid-career women in STEM across Australia and New Zealand.

A minister's assurance that the review was moving to implementation rang hollow after officials cited a postponed, pencilled‑in meeting as evidence that recommendations are already being implemented.

A subtle but significant shift in Budget practice has emerged in Canberra during Senate Estimates, with Health Department officials confirming the reallocation of $2.7 billion in mostly future-program underspends to other portfolio priorities.

The ethics-approved studies to reword definitions are being overshadowed by an apparently inconsistent approach to stakeholder participation and concern in the medical sector, given its sudden inclusion in a process from which it has largely been excluded.

The 2026 Patient's Choice Awards, presented by Patients Australia, will bring together healthcare leaders, clinicians, researchers, patient advocates, carers, policymakers and consumers from across the country for a national celebration of excellence in patient-centred care.